sr141716 has been researched along with Atherogenesis in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (75.00) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dora, JM; Scheffel, RS | 1 |
| Rapezzi, C; Volpe, M | 1 |
| Manzato, E; Marchiori, M; Zambon, A | 1 |
| Bono, F; Desitter, P; Dol-Gleizes, F; Gilde, A; Hennuyer, N; Marés, AM; Paumelle, R; Schaeffer, P; Staels, B; Visentin, V | 1 |
| Pacher, P | 1 |
| Paquot, N; Scheen, AJ | 1 |
| Immenschuh, S | 1 |
| Shwarts, V | 1 |
| Akiyama, E; Fujiwara, Y; Horibata, Y; Kaikita, K; Konishi, M; Maeda, H; Matsubara, J; Matsuzawa, Y; Nozaki, T; Ogawa, H; Ohba, K; Sugamura, K; Sugiyama, S; Sumida, H; Takeya, M | 1 |
| Jung, S; Lütjohann, D; Naehle, CP; Nickenig, G; Tiyerili, V; Wassmann, K; Wassmann, S; Zimmer, A; Zimmer, S | 1 |
| Acharya, A; Balaraman, R; Chatterjee, A; Jain, MR; Mohapatra, J; Pandya, G; Sharma, M | 1 |
| Ditrói, K; Kleiner, D | 1 |
| Cannon, CP; Gelfand, EV | 1 |
| Forrester, JS; Shah, PK | 1 |
| Bhatt, DL; Cannon, CP; Deanfield, JE; Després, JP; Gaudin, C; Hu, B; Job, B; Kapadia, S; Kastelein, JJ; Lincoff, AM; Nicholls, SJ; Nissen, SE; Rodés-Cabau, J; Ruzyllo, W; Steinhubl, SR; Tuzcu, EM; Wolski, K; Yasin, M | 1 |
| Nallamothu, BK; Rumsfeld, JS | 1 |
5 review(s) available for sr141716 and Atherogenesis
| Article | Year |
|---|---|
Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders.
Topics: Atherosclerosis; Blood Glucose; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fasting; Glucose; Glycated Hemoglobin; Humans; Lipid Metabolism; Metabolic Diseases; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors | 2009 |
[Adipose tissue inflammation and atherosclerosis].
Topics: Adipokines; Adipose Tissue; Atherosclerosis; Chemotaxis; Cytokines; Endothelium, Vascular; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Macrophages; Metformin; Obesity; Piperidines; Pyrazoles; Rimonabant; Vasoconstrictor Agents | 2009 |
[The potential use of cannabidiol in the therapy of metabolic syndrome].
Topics: Adipocytes; Appetite Depressants; Atherosclerosis; Cannabidiol; Cannabinoid Receptor Antagonists; Disease Progression; Humans; Hyperphagia; Ischemia; Metabolic Syndrome; Obesity; Piperidines; PPAR gamma; Pyrazoles; Rimonabant | 2012 |
Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors.
Topics: Animals; Atherosclerosis; Blood Glucose; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Lipid Metabolism; Marijuana Abuse; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Smoking Cessation | 2006 |
Emerging strategies for increasing high-density lipoprotein.
Topics: Animals; Apolipoprotein A-I; Atherosclerosis; Cannabinoid Receptor Antagonists; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Humans; Lipoproteins, HDL; Peroxisome Proliferator-Activated Receptors; Piperidines; Pyrazoles; Rimonabant; Risk Factors | 2006 |
1 trial(s) available for sr141716 and Atherogenesis
| Article | Year |
|---|---|
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.
Topics: Aged; Atherosclerosis; Coronary Artery Disease; Coronary Vessels; Diet, Reducing; Disease Progression; Double-Blind Method; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Obesity; Piperidines; Prospective Studies; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Ultrasonography, Interventional | 2008 |
10 other study(ies) available for sr141716 and Atherogenesis
| Article | Year |
|---|---|
Rimonabant and progression of atherosclerosis in obese persons.
Topics: Anti-Obesity Agents; Atherosclerosis; Coronary Artery Disease; Ethics, Research; Humans; Obesity; Piperidines; Placebos; Pyrazoles; Receptor, Cannabinoid, CB1; Research Design; Rimonabant; Ultrasonography | 2008 |
[Residual risk in cardiovascular prevention].
Topics: Atherosclerosis; Blood Pressure; Body Weight; Cannabinoid Receptor Antagonists; Cannabinoids; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Follow-Up Studies; Humans; Hypolipidemic Agents; Kaplan-Meier Estimate; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Risk Factors; Smoking Cessation; Thiazolidines; Time Factors | 2008 |
[Dyslipidemia in visceral obesity: pathophysiological mechanisms, clinical implications and therapy].
Topics: Atherosclerosis; Bradykinin; Cannabinoid Receptor Antagonists; Cannabinoids; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Dyslipidemias; Female; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Meta-Analysis as Topic; Obesity; Piperidines; Prospective Studies; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Sex Factors | 2008 |
Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice.
Topics: Animals; Atherosclerosis; Cannabinoids; Chemokine CCL2; Cholesterol; Cytokines; Energy Intake; Female; Inflammation; Interleukin-12; Mice; Mice, Knockout; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, LDL; Rimonabant | 2009 |
Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns?
Topics: Animals; Atherosclerosis; Cannabinoids; Clinical Trials as Topic; Heart Diseases; Humans; Metabolic Diseases; Mice; Mice, Knockout; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, LDL; Rimonabant; Weight Gain | 2009 |
Endocannabinoid signalling as an anti-inflammatory therapeutic target in atherosclerosis: does it work?
Topics: Amides; Animals; Atherosclerosis; Cannabinoid Receptor Modulators; Disease Models, Animal; Endocannabinoids; Humans; Macrophages; Mice; Piperidines; Pyrazoles; Pyridines; Reactive Oxygen Species; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Signal Transduction | 2009 |
Cannabinoid 1 receptor blockade reduces atherosclerosis with enhances reverse cholesterol transport.
Topics: Adiponectin; Administration, Oral; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Cholesterol; Cholesterol, HDL; Humans; Macrophages; Mice; Mice, Transgenic; Models, Biological; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant | 2010 |
CB1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cells, Cultured; Endothelium, Vascular; Female; In Vitro Techniques; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidative Stress; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Cannabinoid, CB1; Rimonabant | 2010 |
Retinol-binding protein 4 : a possible role in cardiovascular complications.
Topics: 3T3-L1 Cells; Adipokines; Animals; Apolipoprotein E3; Atherosclerosis; Base Sequence; Cardiovascular Diseases; Cholesterol; DNA Primers; Female; Gene Expression Regulation; Hypercholesterolemia; Inflammation; Mice; Mice, Inbred C57BL; Obesity; Piperidines; Pyrazoles; Real-Time Polymerase Chain Reaction; Retinol-Binding Proteins, Plasma; Rimonabant | 2011 |
The hope and fear of rimonabant.
Topics: Atherosclerosis; Humans; Metabolic Syndrome; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk | 2008 |